Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 400-405

  Wu, Xingchen ^a   Pertovaara, Hannu ^a   Korkola, Pasi ^a   Vornanen, Martine ^a   Eskola, Hannu ^a,b   Kellokumpu Lehtinen, Pirkko Liisa ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Diffuse large B cell lymphoma; FDG PET CT; Ki 67 proliferation index; Non Hodgkin's lymphoma; SUVmax

Indexed keywords

GLUCOSE; KI 67 ANTIGEN; PARAFFIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CELL DIVISION; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOLYSIS; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOGRAPHY, INTERVENTIONAL; RADIOPHARMACEUTICALS;

EID: 84863179024     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.622420     Document Type: Article

References (22)

1. Gerdes J, Schwab U, Lemke H.et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20. (Pubitemid 13179545)
2. S cholzen T, Gerdes J. Th e Ki-67 protein: From the known and the unknown. J Cell Physiol 2000;182:311-322. (Pubitemid 30054364)
3. B rown DC, Gatter KC. Ki67 protein: The immaculate deception? Histopathology 2002;40:2-11.
4. B ryant RJ, Banks PM, O'Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 2006;48:505-515.
5. S zczuraszek K, Mazur G, Jelen M.et al. Prognostic signifi cance of Ki-67 antigen expression in non-Hodgkins lymphomas. AntiCancer Res. 2008,28:1113-1118. (Pubitemid 351578962)
6. L apela M, Leskinen S, Minn HR.et al. Increased glucose metabolism in untreated non-Hodgkins lymphoma: A study with positron emission tomography and fl uorine-18-fl uorodeoxyglucose. Blood 1995;86:3522-3527.
7. S choder H, Noy A, Gonen M.et al. Intensity of 18fl uorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkins lymphoma. J. Clin. Oncol. 2005;23:4643-4651. (Pubitemid 46224066)
8. H utchings M, Specht L. PET/CT in the management of haematological malignancies. Eur. J. Haematol. 2008;80:369-380. (Pubitemid 351503112)
9. W u X, Dastidar P, Pertovaara H.et al. Early Treatment Response Evaluation in Patients with Diff use Large B-Cell Lymphoma-A Pilot Study Comparing Volumetric MRI and PET/CT. Mol Imaging Biol 2011;13:785-792.
10. R osenberg SA. Validity of the Ann Arbor staging classifi cation for the non-Hodgkins lymphomas. Cancer Treat Rep 1977;61:1023-1027.
11. A predictive model for aggressive non-Hodgkins lymphoma. Th e International Non-Hodgkins Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993;329:987-994.
12. W ilder RB, Rodriguez MA, Medeiros LJ.et al. International prognostic index-based outcomes for diff use large B-cell lymphomas. Cancer 2002;94:3083-3088. (Pubitemid 34670490)
13. WHO Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. Vol 2 of the WHO series on histological and genetic typing of human tumours Edited by Swerdlow, S.H., Campo, E., Harris, N.L., Jaff e, E.S., Pileri, S.A., Stein, H., Th iele, J., Vardiman, J.W. IARC, Lyon 2008.
14. Weber G. Enzymology of cancer cells (fi rst of two parts). N. Engl. J. Med. 1977;296:486-492.
15. Vander Heiden MG, Cantley LC, Th ompson CB. Understanding the Warburg eff ect: The metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
16. O kada J, Yoshikawa K, Itami M.et al. Positron emission tomography using fl uorine-18-fl uorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 1992;33:325-329.
17. Watanabe R, Tomita N, Takeuchi K.et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:279-283.
18. Papajik T, Myslivecek M, Sedova Z.et al. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with diff erent subtypes of non-Hodgkins lymphoma. Eur. J. Haematol. 2011;86:32-37.
19. Tang B, Malysz J, Douglas-Nikitin V.et al. Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 2009;11:296-302.
20. B odet-Milin C, Kraeber-Bodere F, Moreau P.et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471-472. (Pubitemid 351398655)
21. Noy A, Schoder H, Gonen M.et al. Th e majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diff use large B-cell lymphoma (DLBCL). Ann. Oncol. 2009;20:508-512.
22. Wu X, Korkola P, Pertovaara H.et al. No correlation between glucose metabolism and apparent diff usion coeffi cient in diff use large B-cell lymphoma: A PET/CT and DW-MRI study. Eur. J. Radiol 2011;79:e117-121.